DARA BioSciences Appoints Haywood Cochrane Jr. as Chairman of the Board of Directors and Names Paul Richardson as a New Board

DARA BioSciences Appoints Haywood Cochrane Jr. as Chairman of the Board of 
Directors and Names Paul Richardson as a New Board Member 
RALEIGH, NC -- (Marketwire) -- 03/01/13 --  DARA BioSciences, Inc.
(NASDAQ: DARA) (the "Company" or "DARA"), announced today the
appointments of Haywood D. Cochrane Jr. as chairman of the DARA board
of directors and Paul Richardson as a new board member. 
Mr. Cochrane has served as a member of DARA's board since February
2008. Mr. Cochrane has over 30 years of healthcare experience in
executive and senior management positions, including senior vice
president and chief operating officer of Roche Biomedical
Laboratories, president and chief executive officer of Allied
Clinical Laboratories and executive vice president and chief
financial officer of Laboratory Corporation of America. Mr. Cochrane
earned an A.B. degree in political science from the University of
North Carolina at Chapel Hill where he was a Morehead Scholar. 
"Haywood brings our board extensive executive and senior management
experience in the healthcare industry and extraordinary abilities as
a communicator and board facilitator. His relevant business expertise
and leadership experience acquired through serving as vice chairman
and chairman of the boards of directors of other healthcare-related
companies make Haywood an outstanding choice to serve as the chairman
of the board for DARA," said David J. Drutz, M.D., DARA's chief
executive officer. 
Mr. Richardson had previously served on the board of a public company
specializing in oncology supportive care and has over 30 years of
senior executive experience in the bio-pharmaceutical industry,
culminating in his former position as the President for Pfizer's
North American Specialty Business. 
"Paul is a tenured bio-pharmaceutical executive with far-reaching
experience in global product commercialization and development.
Paul's impressive background further strengthens our board by
providing additional expertise for commercial and developmental
strategy on a worldwide basis," said Dr. Drutz. "His strategic,
managerial and commercial skills combined with his knowledge
regarding specialty products will be of paramount importance as we
grow our business. We look forward to Paul's input as we move forward
with our commercial platform. Furthermore, Paul's contacts and
experience will be invaluable as the company executes on its plan to
continue building its sales and marketing pipeline."  
Dr. Drutz concluded, "We are very grateful to have a board of
directors with the experience, knowledge, and expertise necessary to
support DARA in its ongoing efforts to become a preeminent oncology
and oncology supportive care company." 
About DARA BioSciences, Inc.
 DARA is a specialty pharmaceutical
company focused on the development and commercialization of oncology
treatment and supportive care products. DARA has comprehensive
commercial coverage across the national oncology market through a
series of agreements with a number of specialty pharmacy providers,
leading group purchasing organizations (GPOs), retail partners,
reimbursement experts, and an industry-leading third-party logistics
provider. As part of an integrated national network with annual sales
of over $1 billion in cancer therapeutics, DARA has significant
commercial scale and capabilities. Its distribution network consists
of more than 45,000 retail pharmacies, mail order pharmacies, and
long-term care facilities. This provides DARA with established
reimbursement and logistics expertise, as well as partnering
opportunities with more than 300 sales and marketing personnel
uniquely focused on oncology and oncology support products. This
comprehensive network of partners is rare if not unique among
companies in the oncology supportive care area and provides DARA a
strong foundation for product introductions into this underserved
DARA increased its focus in oncology through its January 2012
acquisition of Oncogenerix, Inc., which holds the exclusive U.S.
marketing rights to Soltamox(R), a novel oral liquid formulation of
tamoxifen citrate, which is widely used in the treatment and
prevention of breast cancer. Soltamox is the only FDA-approved oral
liquid version of tamoxifen citrate and fulfills a vital clinical
need for patients who cannot tolerate existing solid tablet
formulations of this drug. DARA launched Soltamox in October 2012 to
coincide with National Breast Cancer Awareness Month. DARA has
exclusive U.S. rights to Soltamox through a license from Rosemont
Pharmaceuticals, Ltd. Additionally, in June 2012, DARA launched its
first product, Bionect(R), a topical treatment for skin irritation
and burns associated with radiation therapy. DARA has rights to
market Bionect in the US oncology/radiology markets under license
from Innocutis. In September 2012, DARA entered into an exclusive
agreement with the Helsinn Group of Switzerland for U.S. commercial
rights to Gelclair(R), an FDA-cleared product for the treatment of
oral mucositis. DARA plans to launch Gelclair in the first quarter of
Prior to acquiring Oncogenerix, DARA was focused on the development
of a cancer-support therapeutic compound, KRN5500, for the treatment
of neuropathic pain in patients with cancer. This product is an
excellent fit with DARA's strategic oncology focus, has successfully
completed a Phase 2a clinical trial, and has been designated a Fast
Track Drug by the United States Food and Drug Administration. DARA is
working with the National Cancer Institute (NCI) to design an
additional clinical trial under joint DARA-NCI auspices while
continuing further Phase 2 development.  
In addition to its oncology products, DARA's pipeline includes DB959,
a novel, non-TZD dual delta/gamma PPAR agonist for the treatment of
type 2 diabetes and dyslipidemia. DARA has completed Phase 1 testing
of DB959 and is presently pursuing opportunities to out-license this
For more information please visit our web site at www.darabio.com.  
Safe Harbor Statement 
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Those factors include risks
and uncertainties relating to DARA's ability to timely commercialize
and generate revenues or profits from Bionect(R), Soltamox(R),
Gelclair(R) or other products given that DARA onl
y recently hired its
initial sales force and DARA's lack of history as a
revenue-generating company, FDA and other regulatory risks relating
to DARA's ability to market Bionect, Soltamox, Gelclair or other
products in the U.S. or elsewhere, DARA's ability to develop and
bring new products to market as anticipated, DARA's current cash
position and its need to raise additional capital in order to be able
to continue to fund its operations, the current regulatory
environment in which DARA develops and sells its products, the market
acceptance of those products, dependence on partners, successful
performance under collaborative and other commercial agreements,
competition, the strength of DARA's intellectual property and the
intellectual property of others, the potential delisting of DARA's
common stock from the NASDAQ Capital Market, risks and uncertainties
relating to DARA's ability to successfully integrate Oncogenerix and
other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission ("SEC").
Copies of DARA's filings with the SEC may be obtained from the SEC
Internet site at http://www.sec.gov. DARA expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in DARA's expectations with regard thereto or any
change in events, conditions, or circumstances on which any such
statements are based. DARA BioSciences and the DARA logo are
trademarks of DARA BioSciences, Inc.  
Contact for DARA BioSciences, Inc.: 
Jack Domeischel
Fountain Square Communications LLC
Phone: 516.480.8813
Email: jack.fountainsquare@gmail.com 
Press spacebar to pause and continue. Press esc to stop.